OGN Organon: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Public company logo of Organon Corp (OGN)

Organon & Co. management relies on stable demand and the global expansion of its brands. The company's historical EV/EBITDA trend visualizes the results of implementing AI platforms and packaging automation, as well as the costs of expensive thermal logistics control. The value of 6.97 indicates the current level of market valuation, allowing for the determination of the financial stability and investment attractiveness of this pharma business.

Organon Corp - OGN Company Value to EBITDA (period 11/23/2025 - 11/10/2026)

OGN (organon.com): analytical breakdowns and indicator data

- market price and analyst price targets:
Price Chart Organon Corp|OGN - Average Forecast Price
- company stock capitalization data:
Market Value Organon Pharma|OGN - Real Price to Acquire Entire Company
- book value of equity indicators:
Book Value per Share Organon|OGN - Total Stockholders' Equity|Market Value to Book Value Ratio organon.com|OGN - Total Business Assets
- debt level and financial liquidity data:
Debt to Equity Organon & Co.|OGN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Organon|OGN - Aggregate Debt Obligations|Debts to Book Capitalization Organon Pharma|OGN - Long-Term Indebtedness|Company Short-Term Debts Organon|Quick Liquidity organon.com
- financial results and valuation multiples details:
OGN - Company Profit|Expected Profit Organon & Co.|OGN - Market Cap to Earnings|Future Price to Earnings Organon & Co.|OGN - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Organon Pharma|OGN - Income before deduction of interest, taxes and amortization|Earnings per share for the last 12 months Organon|OGN - Earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months organon.com|OGN - Earnings per share increase in current year|Earnings growth forecast for next year Organon & Co.
Summary company analysis:Organon Corp OGN
Original product of Organon

Organon & Co. (OGN) pursues an aggressive strategy of acquiring women's health startups, which necessitates strict control over debt leverage during the integration of new assets. This EV/EBITDA multiple chart, with a value of 6.97, compares the total enterprise value with operating profit, allowing investors to assess the capital payback period and the risks of underestimating cash flow amid high indebtedness.

Main competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dare Bioscience Inc. DARE|TherapeuticsMD Inc (TXMD) - Company Value to EBITDA|PTN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization